DRD

Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Obsidian, TIL, University, ICI, AACR, Annual general meeting, Safety, MD Anderson Cancer Center, DRD, Therapy, Cytokine, Patient, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during the American Association of Cancer Research (AACR) Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during the American Association of Cancer Research (AACR) Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.
  • These data follow the announcement of positive top-line results from the ongoing first-in-human, Phase 1 clinical trial evaluating the safety and efficacy of OBX-115, Obsidian’s lead engineered TIL cell therapy candidate, in patients with metastatic melanoma that has relapsed and/or is refractory to prior immune checkpoint inhibitor (ICI) therapy ( NCT05470283 ).
  • The details of these posters are as follows:
    Presenting Author: Rodabe N Amaria, The University of Texas MD Anderson Cancer Center, Houston, TX

DRDGOLD Limited Announces Participation in 121 Mining Investment Conference in Cape Town

Retrieved on: 
Monday, January 15, 2024
DRDGOLD Limited, DRD, Conference, Mining

Johannesburg, South Africa--(Newsfile Corp. - January 15, 2024) - DRDGOLD Limited (JSE: DRD) (A2X: DRD) (NYSE: DRD) is pleased to announce the company is participating in the upcoming 121 Mining Investment Conference in Cape Town.

Key Points: 
  • Johannesburg, South Africa--(Newsfile Corp. - January 15, 2024) - DRDGOLD Limited (JSE: DRD) (A2X: DRD) (NYSE: DRD) is pleased to announce the company is participating in the upcoming 121 Mining Investment Conference in Cape Town.
  • 121 Mining Investment Cape Town will be hosting over 125 mining companies and more than 550 sophisticated investors for two days of pre-arranged, targeted 1-2-1 meetings.
  • Alongside the curated schedule of pre-booked meetings matching investors with appropriate projects, the conference programme will provide expert commentary and the latest market intelligence on key industry developments.
  • Any investors who would like to attend 121 Mining Investment Cape Town can register for a free pass here: https://hubs.la/Q02f4pD60

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science

Retrieved on: 
Wednesday, December 13, 2023
Annual Reviews (publisher), ASH, BTK, Research, Bortezomib, Omicron, Conference, Bangladesh Technical Education Board, Poster, Mantle cell lymphoma, SLL, Risk, Science, Abstract, Drug development, Tyrosine kinase, Society, B-cell lymphoma, FACP, Rituximab, Reversibility, Delta, Phase, Nivolumab, Hospital, Safety, DRD, MCL, FCS, FDA, Lymphocytosis, Pivotal trial, Chronic lymphocytic leukemia, Meta-analysis, Artery, Bias, Coronary thrombosis, NHL, CLL, Pharmaceutical industry, Dietary supplement, Vaccine, Birth control, Incidence, Patient, Dexamethasone, Lenalidomide, Hematology, Relapse, Dacarbazine, MD, Doxorubicin

FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023. Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.

Key Points: 
  • FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023.
  • Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.
  • Pirtobrutinib has also been approved for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
  • Once again, FCS is proud to have a strong presence, sharing the latest and most promising research and science that is moving the field forward."

Lucio N. Gordan, MD is Lead Author of First Real-World Study Comparing Preferred Treatments for Multiple Myeloma

Retrieved on: 
Wednesday, November 22, 2023
Bone marrow, End organ damage, Immune system, Food, Multiple myeloma, DRD, Progression-free survival, Risk, FCS, Clinical trial, TIE, Patient, PFS, Lenalidomide, Death, HIV disease progression rates, Vaccine, Pharmaceutical industry, Dexamethasone, ScienceDirect

FORT MYERS, Fla., Nov. 22, 2023 /PRNewswire/ -- Medical oncologist Lucio N. Gordan MD, president and managing physician of Florida Cancer Specialists & Research Institute, LLC (FCS), is lead author of the first real-world study comparing the two preferred regimens recommended for the primary treatment of non-transplant patients with newly-diagnosed multiple myeloma, published recently in Science Direct. Results of the study to assess optimal clinical treatment strategies were reported in the article entitled, "Progression-Free Survival of Daratumumab (DRd) Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone (VRd) in Transplant Ineligible Patients (TIE) With Newly Diagnosed Multiple Myeloma (NDMM): TAURUS Chart Review Study."

Key Points: 
  • Results of the study to assess optimal clinical treatment strategies were reported in the article entitled, "Progression-Free Survival of Daratumumab (DRd) Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone (VRd) in Transplant Ineligible Patients (TIE) With Newly Diagnosed Multiple Myeloma (NDMM): TAURUS Chart Review Study."
  • However, previous to the TAURUS study, no direct head-to-head clinical trial had been conducted to compare the efficacy of the two regimens.
  • Cancerous tumors can weaken the body's immune system, damage bones and lead to end-organ damage.
  • MM is the second most common hematologic malignancy in the U.S. Two thirds of newly diagnosed patients are 65 years or older.

DRDGOLD Limited Announces Participation in the 121 Mining Investment Conference in London

Retrieved on: 
Thursday, November 9, 2023
JSE, DRDGOLD Limited, Conference, Mining, NYSE, DRD, Cryptocurrency

Johannesburg, South Africa--(Newsfile Corp. - November 9, 2023) - DRDGOLD Limited (JSE: DRD) (A2X: DRD) (NYSE: DRD) is pleased to announce the Company's participation in the upcoming 121 Mining Investment Conference in London.

Key Points: 
  • Johannesburg, South Africa--(Newsfile Corp. - November 9, 2023) - DRDGOLD Limited (JSE: DRD) (A2X: DRD) (NYSE: DRD) is pleased to announce the Company's participation in the upcoming 121 Mining Investment Conference in London.
  • DRDGOLD's Niël Pretorius: Chief Executive Officer and Mpho Mashatola: Group Financial Manager will present the Company's recent and future planned activities.
  • 121 Mining Investment London will host over 175 mining companies and more than 500 sophisticated investors for two days of pre-arranged, targeted 1-2-1 meetings.
  • Any investors who would like to attend 121 Mining Investment London can register for a free pass here: https://hubs.la/Q026gbp80 .

DRDGOLD Limited to Present at Investor Summit Group's Q4 Conference

Retrieved on: 
Tuesday, November 8, 2022
Sheraton New York Times Square Hotel, Thought, Mining, DRD, NYSE, ESG, The Retreat, Gold, Longevity, Adoption, JSE Limited, Sibanye-Stillwater, Seventh Avenue, New, DRDGOLD Limited, Company, Sustainable development, JSE

Johannesburg, South Africa--(Newsfile Corp. - November 8, 2022) - DRDGOLD Limited (JSE: DRD) (NYSE: DRD), today announced that Niel Pretorius, Chief Executive Officer of DRDGOLD Limited will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.

Key Points: 
  • Johannesburg, South Africa--(Newsfile Corp. - November 8, 2022) - DRDGOLD Limited (JSE: DRD) (NYSE: DRD), today announced that Niel Pretorius, Chief Executive Officer of DRDGOLD Limited will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.
  • During the presentation, DRDGOLD's Chief Executive Officer, Niel Pretorius, will introduce the Company and its value proposition of gold-price exposure, ESG and dividend history.
  • The presentation will be made available on the DRDGOLD website at www.drdgold.com on 14th November 2022.
  • ET
    Location: Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York, NY 10019
    The conference is completely complimentary to qualified investors.

Neuron Mobility’s industry-leading e-scooters will begin rolling out in Ottawa this week with a range of technology enhancements

Retrieved on: 
Wednesday, July 6, 2022
CAD, GPS, Golden Triangle, Transport, CEO, Pedestrian, Research, Travel, Adoption, App store, GLOBE, Severe cognitive impairment, DRD, Mark (given name), Human voice, Friends, Industry, Map, Smartphone, CO2, Restaurant, Gaps, United Kingdom, Partnership, Social media, Human, Technology, Vehicle horn, Google Play, City, ByWard Market, Safety, Google Maps, Family, HALT, New World First Bus, TIRF, RGD, Program, Education, Surveying, Road, Taxicab, Ridesharing company, Satellite navigation device, Neuron

With the new controls and technology being introduced, Ottawa will become home to one of the worlds most advanced e-scooter programs.

Key Points: 
  • With the new controls and technology being introduced, Ottawa will become home to one of the worlds most advanced e-scooter programs.
  • Ottawa was one of four cities worldwide where these technologies were extensively tested prior to this year.
  • Ottawa is the first city in the world to feature our High Accuracy Location Technology across an entire e-scooter fleet.
  • The e-scooters will be rolling out onto Ottawa streets in phases determined through close collaboration with the City of Ottawa.

Basic Precious and Non-Ferrous Metals Manufacture in South Africa 2021: High Electricity Costs and Inconsistent Supply - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 30, 2021
Mining, Minerals, Natural Resources, DRD, Sibanye-Stillwater, Gold, Metal, African, Gold Fields, Electricity, Anglo American Platinum, Industry, Recycling, Mining

The "Manufacture of Basic Precious and Non-Ferrous Metals in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Manufacture of Basic Precious and Non-Ferrous Metals in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.
  • Local manufacturers of basic precious and non-ferrous metals are benefiting from rising prices for most metals in response to the recovery of the world economy, and South African exports of basic precious and non-ferrous metals have increased significantly as a result.
  • Factors such as the impact of the pandemic, high input costs and the inconsistent supply of electricity continue to have a significant impact on the performance of the sector.
  • Smelters use large amounts of electricity in the production of metals, and a consistent supply of electricity is needed to prevent interruptions to production.

Canada's National Strategy for Drugs for Rare Diseases Needs a Holistic Approach

Retrieved on: 
Wednesday, December 8, 2021
Data collection, Benefit, TAK, Takeda, Patient, Takeda Pharmaceutical Company, Standards for Better Health, Case report, Quality of life, Forum, Degenerative disease, Sant, DRD, R, Science, Vaccine, Policy, General manager, Rare, Translation, Marketing, Diagnosis, Health Canada, National Strategy for Trusted Identities in Cyberspace, Investment, Federal, Pharmaceutical industry, Medical device

Takeda's longstanding commitment to Drugs for Rare Diseases (DRD) and extensive global footprint provides a unique opportunity to assess and summarize best practices on how different countries have developed their own tailored approaches to expediting and expanding access to new treatments for rare diseases.

Key Points: 
  • Takeda's longstanding commitment to Drugs for Rare Diseases (DRD) and extensive global footprint provides a unique opportunity to assess and summarize best practices on how different countries have developed their own tailored approaches to expediting and expanding access to new treatments for rare diseases.
  • Many jurisdictions have adopted a holistic approach to treating rare diseases one that embeds a set of specific protocols and processes within an overarching policy framework that incorporates multiple measures to support people with rare disease needs.1These countries recognize that drugs for rare diseases are only one essential part of a robust rare disease strategy.
  • The strategy must also address improved screening, timely diagnosis, data collection and patient and caregiver support.
  • "Canada has the unique opportunity to learn from other jurisdictions to create real and meaningful change for Canadians living with rare diseases.

American Commercial Barge Line (ACBL) Found Not at Fault for 2008 Mississippi River Collision and Oil Spill

Retrieved on: 
Wednesday, December 8, 2021
Environment, Monarto Woodlands Conservation Park, Grain, Culture, Safety, Recreation, River, Industry, Mel Oliver and Space Rover on Mars, Mississippi River, Grand Isle State Park (Louisiana), OPA, ACBL, DRD, Oil, Transport, Justice, Multimedia, U.S. Department of Defense Strategy for Operating in Cyberspace, U.S. Department of Justice Office of Legislative Affairs, Acquisition, Oil Pollution Act of 1990, Road, Dredging, Insurance, Rail freight transport

JEFFERSONVILLE, Ind., Dec. 8, 2021 /PRNewswire/ --Following more than 13 years of legal proceedings, American Commercial Barge Line (ACBL) has been cleared of any fault related to the 2008 M/V Mel Oliver collision and resulting oil spill on the Mississippi River.

Key Points: 
  • JEFFERSONVILLE, Ind., Dec. 8, 2021 /PRNewswire/ --Following more than 13 years of legal proceedings, American Commercial Barge Line (ACBL) has been cleared of any fault related to the 2008 M/V Mel Oliver collision and resulting oil spill on the Mississippi River.
  • It was determined DRD Towing was entirely at fault for the collision and resulting oil spill.
  • DRD Towing operated and crewed the M/V Mel Oliver, which was towing the ACBL-owned DM-932 barge at the time of the collision.
  • Today, ACBL has one of the nation's newest inland river barge fleets operating along 7,200 miles of U.S. inland waterways.